CytoMed Therapeutics Ltd GDTC
CytoMed Therapeutics Ltd (Nasdaq: GDTC) is an oncology drug developer. Its lead program, CTM-N2D, is in Phase 1 for cancer (ANGELICA safety trial; specific tumor type not stated in extract). Its next catalyst on record is CTM-N2D (ANGELICA): Recruit additional patients (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CTM-N2D (ANGELICA) — Recruit additional patients (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CTM-N2D (NKG2DL-targeting CAR gamma delta T cells) | cancer | cell therapy | Phase 1 |
| iPSC-gdNKT | cancer | cell therapy | Pre-clinical |
| CTM-NK | cancer | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.